Seres Therapeutics, Inc. (MCRB) Shares Sold by Goldman Sachs Group Inc.

Goldman Sachs Group Inc. decreased its holdings in shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) by 47.5% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 23,315 shares of the biotechnology company’s stock after selling 21,103 shares during the quarter. Goldman Sachs Group Inc. owned 0.06% of Seres Therapeutics worth $263,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also modified their holdings of the company. Vanguard Group Inc. grew its holdings in shares of Seres Therapeutics by 1.2% during the second quarter. Vanguard Group Inc. now owns 1,585,026 shares of the biotechnology company’s stock valued at $17,911,000 after buying an additional 19,363 shares in the last quarter. Ark Investment Management LLC grew its holdings in shares of Seres Therapeutics by 21.5% during the second quarter. Ark Investment Management LLC now owns 765,191 shares of the biotechnology company’s stock valued at $8,647,000 after buying an additional 135,276 shares in the last quarter. Northern Trust Corp grew its holdings in shares of Seres Therapeutics by 16.2% during the second quarter. Northern Trust Corp now owns 235,766 shares of the biotechnology company’s stock valued at $2,664,000 after buying an additional 32,875 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Seres Therapeutics by 5.8% during the first quarter. Geode Capital Management LLC now owns 166,325 shares of the biotechnology company’s stock valued at $1,874,000 after buying an additional 9,060 shares in the last quarter. Finally, TIAA CREF Investment Management LLC grew its holdings in shares of Seres Therapeutics by 14.4% during the first quarter. TIAA CREF Investment Management LLC now owns 110,076 shares of the biotechnology company’s stock valued at $1,241,000 after buying an additional 13,825 shares in the last quarter. Institutional investors and hedge funds own 74.77% of the company’s stock.

Seres Therapeutics, Inc. (NASDAQ:MCRB) opened at $9.41 on Friday. The company has a quick ratio of 6.53, a current ratio of 6.53 and a debt-to-equity ratio of 0.11. Seres Therapeutics, Inc. has a 52 week low of $8.85 and a 52 week high of $17.42.

Seres Therapeutics (NASDAQ:MCRB) last issued its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.17) EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.22. Seres Therapeutics had a negative return on equity of 82.11% and a negative net margin of 267.15%. The firm had revenue of $23.00 million for the quarter, compared to the consensus estimate of $17.29 million. During the same quarter in the previous year, the company posted ($0.46) earnings per share. The business’s quarterly revenue was up 76.9% compared to the same quarter last year. research analysts anticipate that Seres Therapeutics, Inc. will post -2.34 EPS for the current year.

MCRB has been the topic of a number of research analyst reports. Zacks Investment Research downgraded Seres Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th. Citigroup Inc. initiated coverage on Seres Therapeutics in a report on Thursday, October 12th. They set a “positive” rating and a $19.00 price target on the stock. CIBC initiated coverage on Seres Therapeutics in a report on Friday, October 13th. They set an “outperform” rating and a $19.00 price target on the stock. Oppenheimer Holdings, Inc. initiated coverage on Seres Therapeutics in a report on Thursday, October 12th. They set an “outperform” rating and a $19.00 price target on the stock. Finally, Seaport Global Securities reiterated a “buy” rating and set a $20.00 price target on shares of Seres Therapeutics in a report on Friday, October 6th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the company. Seres Therapeutics presently has an average rating of “Buy” and an average price target of $18.00.

WARNING: This news story was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at https://ledgergazette.com/2017/11/19/seres-therapeutics-inc-mcrb-shares-sold-by-goldman-sachs-group-inc.html.

About Seres Therapeutics

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Institutional Ownership by Quarter for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply